Skip to main content
Erschienen in: World Journal of Urology 1/2016

01.01.2016 | Original Article

Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest

verfasst von: Yannick Cerantola, Eléonore Haberer, Jose Torres, Mona Alameldin, Samuel Aronson, Mark Levental, Franck Bladou, Maurice Anidjar

Erschienen in: World Journal of Urology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prostate cancer (PCa) diagnosis relies on clinical suspicion leading to systematic transrectal ultrasound-guided biopsy (TRUSGB). Multiparametric magnetic resonance imaging (mpMRI) allows for targeted biopsy of suspicious areas of the prostate instead of random 12-core biopsy. This method has been shown to be more accurate in detecting significant PCa. However, the precise spatial accuracy of cognitive targeting is unknown.

Methods

Consecutive patients undergoing mpMRI-targeted TRUSGB with cognitive registration (MRTB-COG) followed by robot-assisted radical prostatectomy were included in the present analysis. The regions of interest (ROIs) involved by the index lesion reported on mpMRI were subsequently targeted by two experienced urologists using the cognitive approach. The 27 ROIs were used as spatial reference. Mapping on radical prostatectomy specimen was used as reference to determine true-positive mpMRI findings. Per core correlation analysis was performed.

Results

Forty patients were included. Overall, 40 index lesions involving 137 ROIs (mean ROIs per index lesion 3.43) were identified on MRI. After correlating these findings with final pathology, 117 ROIs (85 %) were considered as true-positive lesions. A total of 102 biopsy cores directed toward such true-positive ROIs were available for final analysis. Cognitive targeted biopsy hit the target in 82 % of the cases (84/102). The only identified risk factor for missing the target was an anterior situated ROI (p = 0.01).

Conclusion

In experienced hands, cognitive MRTB-COG allows for an accuracy of 82 % in hitting the correct target, given that it is a true-positive lesion. Anterior tumors are less likely to be successfully targeted.
Literatur
1.
Zurück zum Zitat Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488PubMedCrossRef Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16(3):481–488PubMedCrossRef
4.
Zurück zum Zitat Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR et al (2015) In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? BJU Int 115(4):562–570PubMedCrossRef Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR et al (2015) In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? BJU Int 115(4):562–570PubMedCrossRef
5.
Zurück zum Zitat Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L et al (2013) Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 63(1):125–140PubMedCrossRef Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L et al (2013) Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 63(1):125–140PubMedCrossRef
6.
Zurück zum Zitat Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313(4):390–397PubMedPubMedCentralCrossRef Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N et al (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313(4):390–397PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA et al (2014) Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol 192(5):1367–1373PubMedPubMedCentralCrossRef Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA et al (2014) Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol 192(5):1367–1373PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M et al (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology 268(2):461–469PubMedCrossRef Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M et al (2013) Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology 268(2):461–469PubMedCrossRef
9.
Zurück zum Zitat Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO et al (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29PubMedCrossRef Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO et al (2014) Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 66(1):22–29PubMedCrossRef
10.
Zurück zum Zitat Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J et al (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719PubMedCrossRef Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J et al (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719PubMedCrossRef
11.
Zurück zum Zitat Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS et al (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group. Eur Urol 64(4):544–552PubMedCrossRef Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Futterer JJ, Gill IS et al (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an international working group. Eur Urol 64(4):544–552PubMedCrossRef
13.
Zurück zum Zitat Puech P, Ouzzane A, Gaillard V, Betrouni N, Renard B, Villers A et al (2014) Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. BioMed Res Int 2014:819360PubMedPubMedCentralCrossRef Puech P, Ouzzane A, Gaillard V, Betrouni N, Renard B, Villers A et al (2014) Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. BioMed Res Int 2014:819360PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Logan JK, Rais-Bahrami S, Turkbey B, Gomella A, Amalou H, Choyke PL et al (2014) Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int 114(5):641–652PubMedPubMedCentralCrossRef Logan JK, Rais-Bahrami S, Turkbey B, Gomella A, Amalou H, Choyke PL et al (2014) Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int 114(5):641–652PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB et al (2014) Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol 192(3):648–658PubMedPubMedCentralCrossRef Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB et al (2014) Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol 192(3):648–658PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM et al (2014) A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 66(2):343–351PubMedCrossRef Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM et al (2014) A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 66(2):343–351PubMedCrossRef
17.
Zurück zum Zitat Ploussard G, Aronson S, Pelsser V, Levental M, Anidjar M, Bladou F (2014) Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion. World J Urol 32(4):977–983PubMedCrossRef Ploussard G, Aronson S, Pelsser V, Levental M, Anidjar M, Bladou F (2014) Impact of the type of ultrasound probe on prostate cancer detection rate and characterization in patients undergoing MRI-targeted prostate biopsies using cognitive fusion. World J Urol 32(4):977–983PubMedCrossRef
18.
Zurück zum Zitat Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ et al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494PubMedCrossRef Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ et al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494PubMedCrossRef
19.
Zurück zum Zitat Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS et al (2011) Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 108(8 Pt 2):E171–E178PubMedCrossRef Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS et al (2011) Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 108(8 Pt 2):E171–E178PubMedCrossRef
20.
Zurück zum Zitat Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933–938PubMedCrossRef Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933–938PubMedCrossRef
21.
Zurück zum Zitat Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2):2407–2411PubMed Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2):2407–2411PubMed
22.
Zurück zum Zitat Bains LJ, Studer UE, Froehlich JM, Giannarini G, Triantafyllou M, Fleischmann A et al (2014) Diffusion-weighted magnetic resonance imaging detects significant prostate cancer with high probability. J Urol 192(3):737–742PubMedCrossRef Bains LJ, Studer UE, Froehlich JM, Giannarini G, Triantafyllou M, Fleischmann A et al (2014) Diffusion-weighted magnetic resonance imaging detects significant prostate cancer with high probability. J Urol 192(3):737–742PubMedCrossRef
23.
Zurück zum Zitat Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M et al (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794. doi:10.1016/j.eururo.2014.08.077 PubMedCrossRef Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M et al (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794. doi:10.​1016/​j.​eururo.​2014.​08.​077 PubMedCrossRef
24.
25.
Zurück zum Zitat Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ et al (2013) Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 63(2):214–230PubMedCrossRef Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ et al (2013) Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 63(2):214–230PubMedCrossRef
26.
Zurück zum Zitat Cornud F, Khoury G, Bouazza N, Beuvon F, Peyromaure M, Flam T et al (2014) Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 191(5):1272–1279PubMedCrossRef Cornud F, Khoury G, Bouazza N, Beuvon F, Peyromaure M, Flam T et al (2014) Tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol 191(5):1272–1279PubMedCrossRef
27.
Zurück zum Zitat Valerio M, Ahmed HU (2014) Re: tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?: F. Cornud, G. Khoury, N. Bouazza, F. Beuvon, M. Peyromaure, T. Flam, M. Zerbib, P. Legmann, N. B. Delongchamps J Urol 2014; 191: 1272–1279. J Urol 192(4):1297–1298PubMedCrossRef Valerio M, Ahmed HU (2014) Re: tumor target volume for focal therapy of prostate cancer-does multiparametric magnetic resonance imaging allow for a reliable estimation?: F. Cornud, G. Khoury, N. Bouazza, F. Beuvon, M. Peyromaure, T. Flam, M. Zerbib, P. Legmann, N. B. Delongchamps J Urol 2014; 191: 1272–1279. J Urol 192(4):1297–1298PubMedCrossRef
28.
Zurück zum Zitat Turkbey B, Mani H, Aras O, Rastinehad AR, Shah V, Bernardo M et al (2012) Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 188(4):1157–1163PubMedCrossRef Turkbey B, Mani H, Aras O, Rastinehad AR, Shah V, Bernardo M et al (2012) Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 188(4):1157–1163PubMedCrossRef
29.
Zurück zum Zitat Schreiber D, Wong AT, Rineer J, Weedon J, Schwartz D (2015) Prostate biopsy concordance in a large population-based sample: a surveillance, epidemiology and end results study. J Clin Pathol. doi:10.1136/jclinpath-2014-202767 PubMed Schreiber D, Wong AT, Rineer J, Weedon J, Schwartz D (2015) Prostate biopsy concordance in a large population-based sample: a surveillance, epidemiology and end results study. J Clin Pathol. doi:10.​1136/​jclinpath-2014-202767 PubMed
Metadaten
Titel
Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest
verfasst von
Yannick Cerantola
Eléonore Haberer
Jose Torres
Mona Alameldin
Samuel Aronson
Mark Levental
Franck Bladou
Maurice Anidjar
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1588-2

Weitere Artikel der Ausgabe 1/2016

World Journal of Urology 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.